Table 1 Clinical trials for cancer therapies involving ARID1A
From: The effects of ARID1A mutation in gastric cancer and its significance for treatment
Number | Study types | Status | Phase | Cancer types | Intervention | Primary endpoint |
|---|---|---|---|---|---|---|
NCT04065269 | Interventional (Clinical Trial) | Recruiting | II | Gynecological Cancers | ATR inhibitor (AZD6738), PARP inhibitor (Olaparib) | ORR |
NCT04957615 | Interventional (Clinical Trial) | Recruiting | II | Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm | Nivolumab | ORR, OS |
NCT05523440 | Interventional (Clinical Trial) | Recruiting | II | Recurrent Endometrial Carcinoma Recurrent Ovarian Carcinoma | Bevacizumab, Niraparib | ORR |
NCT05690035 | Interventional (Clinical Trial) | Not yet recruiting | II | Metastatic Colorectal Cancer | Tislelizumab & Fruquintinib | ORR |
NCT04953104 | Interventional (Clinical Trial) | Not yet recruiting | II | Urologic Neoplasms | Nivolumab | ORR, OS |
NCT03682289 | Interventional (Clinical Trial) | Recruiting | II | Solid Tumors | Ceralasertib, Olaparib, Durvalumab | ORR |
NCT04042831 | Interventional (Clinical Trial) | Recruiting | II | Advanced Biliary Tract Cancer | Olaparib | ORR |
NCT04284202 | Interventional (Clinical Trial) | Unknown | II | NSCLC Stage IV | PD-1 plus Dasatinib | PFS |